Custom chemo doses may boost survival in rare inherited blood cancers

NCT ID NCT07524530

First seen Apr 18, 2026 · Last updated Jun 08, 2026 · Updated 12 times

Summary

This study tests a stem cell transplant approach for people aged 4 to 70 whose blood cancer is caused by an inherited RUNX1 gene mutation. The key idea is to tailor chemotherapy and supportive care doses to each patient, aiming for better disease-free survival than standard methods. Participants will receive a transplant from a half-matched donor and be followed for 3 years. The study also includes donors, relatives, and healthy volunteers for comparison.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.